Malignant Genitourinary System Neoplasm clinical trials
22 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
- BladdEr Full OR Empty for Pelvic Radiation Therapy
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- Effectiveness of Central Oncology Navigation and the Use of an ORN
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
- Cancer Genetic Testing in Ethnic Populations
- Discharge Medication Use Post-Operatively in GU Cancer Patients
- Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
- A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
- Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
- Cancer and Mild Cognitive Impairment Dyadic Intervention
- Feasibility Study of CBCT for IGRT in Cancer Patients
- Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers
- A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
- Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
- Social Needs App for Oncology Patients Phase II
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Malignant Genitourinary System Neoplasm” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.